# Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases

> **NCT00519064** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 361 (actual)

## Conditions studied

- Influenza Disease

## Interventions

- **BIOLOGICAL:** Adjuvanted influenza vaccine

## Key facts

- **NCT ID:** NCT00519064
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2006-12
- **Final completion:** 2007-05
- **Target enrollment:** 361 (ACTUAL)
- **Last updated:** 2016-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00519064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00519064, "Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00519064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*